These options minimize empty calories while supporting steady energy levels
It is therefore in this context, where treatment options for obesity remain very limited, that the appearance of Ozempic and Mounjaro on the market is currently generating enormous interest, both in the medical and scientific communities and in the general population
Medicare Obesity Coverage Expansion (Regulatory): The Centers for Medicare & Medicaid Services (CMS) announced that beginning in April 2026, Medicare will cover GLP-1 medications for beneficiaries with obesity and qualifying comorbidities via the BALANCE Model and Section 402 demonstrations, marking a reversal of the long-standing statutory ban on weight-loss drug coverage
Implications for the GLP-1 market: More employers will get ahead of the high costs associated with rising GLP-1 use by significantly restricting or eliminating coverage for the drugs, particularly as new oral formulations broaden their appeal
Oral semaglutide was superior to placebo and other antihyperglycemic drugs, such as iDPP4 (sitagliptin), iSGLT2 (empagliflozin) or other arGLP-1 (liraglutide) in reducing HbA1c or weight.116 Oral semaglutide was well tolerated, with a safety profile similar to that of other arGLP-1 s
